ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för 4-(2-methyl-3-propan-2-yl-4-imidazolyl)-N-(4-methylsulfonylphenyl)-2-pyrimidinamine. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

14 träffar

Bibliografisk träff 2024-04-02

Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications.

Zhang Y, Shan L, Tang W, Ge Y, Li C, Zhang J.

J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/acs.jmedchem.4c00312

Bibliografisk träff 2024-03-15

Identification of a Novel Selective CDK9 Inhibitor for the Treatment of CRC: Design, Synthesis, and Biological Activity Evaluation.

Zhong Y, Xu J, Zhou R, Tang L, Ding S, Ren Z, Song N, Hu B, Yang H, Sun Y, Cheng M, Li J, Liu Y.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.3c02329

Bibliografisk träff 2023-12-20

Discovery of pyrazolo[3,4-d]pyrimidines as novel mitogen-activated protein kinase kinase 3 (MKK3) inhibitors.

Takarada JE, Cunha MR, Almeida VM, Vasconcelos SNS, Santiago AS, Godoi PH, Salmazo A, Ramos PZ, Fala AM, de Souza LR, Da Silva IEP, Bengtson MH, Massirer KB, Couñago RM.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2023.117561

Bibliografisk träff 2021-09-20

AZD5438-PROTAC: A selective CDK2 degrader that protects against cisplatin- and noise-induced hearing loss.

Hati S, Zallocchi M, Hazlitt R, Li Y, Vijayakumar S, Min J, Rankovic Z, Lovas S, Zuo J.

Eur J Med Chem · research-article; journal article · DOI 10.1016/j.ejmech.2021.113849

Bibliografisk träff 2020-07-15

A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents.

Marak BN, Dowarah J, Khiangte L, Singh VP.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2020.112571

Bibliografisk träff 2019-06-22

Discovery of novel pyrimidine-based benzothiazole derivatives as potent cyclin-dependent kinase 2 inhibitors with anticancer activity.

Diao PC, Lin WY, Jian XE, Li YH, You WW, Zhao PL.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2019.06.055

Bibliografisk träff 2018-10-26

Screening of the Pathogen Box reveals new starting points for anti-trypanosomal drug discovery.

Veale CGL, Hoppe HC.

Medchemcomm · research-article; journal article · DOI 10.1039/c8md00319j

Bibliografisk träff 2018-08-24

Development of Second-Generation CDK2 Inhibitors for the Prevention of Cisplatin-Induced Hearing Loss.

Hazlitt RA, Teitz T, Bonga JD, Fang J, Diao S, Iconaru L, Yang L, Goktug AN, Currier DG, Chen T, Rankovic Z, Min J, Zuo J.

J Med Chem · research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1021/acs.jmedchem.8b00669

Bibliografisk träff 2018-04-16

Homogeneous Assay for Target Engagement Utilizing Bioluminescent Thermal Shift.

Dart ML, Machleidt T, Jost E, Schwinn MK, Robers MB, Shi C, Kirkland TA, Killoran MP, Wilkinson JM, Hartnett JR, Zimmerman K, Wood KV.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.8b00081

Bibliografisk träff 2017-12-01

The target landscape of clinical kinase drugs.

Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, Reinecke M, Ruprecht B, Petzoldt S, Meng C, Zecha J, Reiter K, Qiao H, Helm D, Koch H, Schoof M, Canevari G, Casale E, Depaolini SR, Feuchtinger A, Wu Z, Schmidt T, Rueckert L, Becker W, Huenges J, Garz AK, Gohlke BO, Zolg DP, Kayser G, Vooder T, Preissner R, Hahne H, Tõnisson N, Kramer K, Götze K, Bassermann F, Schlegl J, Ehrlich HC, Aiche S, Walch A, Greif PA, Schneider S, Felder ER, Ruland J, Médard G, Jeremias I, Spiekermann K, Kuster B.

Science · research support, non-u.s. gov't; research-article; journal article · DOI 10.1126/science.aan4368

Bibliografisk träff 2016-08-01

Discovery and antiparasitic activity of AZ960 as a Trypanosoma brucei ERK8 inhibitor.

Valenciano AL, Ramsey AC, Santos WL, Mackey ZB.

Bioorg Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmc.2016.07.069

Bibliografisk träff 2008-10-25

The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing.

Jones CD, Andrews DM, Barker AJ, Blades K, Daunt P, East S, Geh C, Graham MA, Johnson KM, Loddick SA, McFarland HM, McGregor A, Moss L, Rudge DA, Simpson PB, Swain ML, Tam KY, Tucker JA, Walker M.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2008.10.102

Bibliografisk träff 2008-10-22

Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors.

Jones CD, Andrews DM, Barker AJ, Blades K, Byth KF, Finlay MR, Geh C, Green CP, Johannsen M, Walker M, Weir HM.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2008.10.075

Bibliografisk träff 2008-09-10

Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors.

Anderson M, Andrews DM, Barker AJ, Brassington CA, Breed J, Byth KF, Culshaw JD, Finlay MR, Fisher E, McMiken HH, Green CP, Heaton DW, Nash IA, Newcombe NJ, Oakes SE, Pauptit RA, Roberts A, Stanway JJ, Thomas AP, Tucker JA, Walker M, Weir HM.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2008.09.024